Daclizumab to Treat Chronic Immune Thrombocytopenia

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2002

Study Completion Date

December 31, 2004

Conditions

Thrombocytopenia

Interventions

DRUG

Daclizumab

Trial Locations (1)

Warren G. Magnuson Clinical Center (CC), Bethesda

All Listed Sponsors

lead

National Institutes of Health Clinical Center (CC)

NIH

NCT00049725 - Daclizumab to Treat Chronic Immune Thrombocytopenia | Biotech Hunter | Biotech Hunter